Complicated Intra-Abdominal Infections Clinical Pipeline | 15+ Companies Pioneering the Next Breakthroughs

The Complicated Intra-Abdominal Infections market is evolving with cutting-edge research and new therapeutic advancements.

DelveInsight's 'Complicated Intra-Abdominal Infections Pipeline Insight 2024' report provides comprehensive global coverage of pipeline Complicated Intra-Abdominal Infections therapies in various stages of clinical development. Major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Complicated Intra-Abdominal Infections pipeline domain.

For Complicated Intra-Abdominal Infections emerging drugs, the Complicated Intra-Abdominal Infections pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

Key Takeaways from the Complicated Intra-Abdominal Infections Pipeline Report
• DelveInsight's Complicated Intra-Abdominal Infections Pipeline analysis depicts a robust space with 15+ active players working to develop 15+ pipeline drugs for Complicated Intra-Abdominal Infections treatment.
• The leading Complicated Intra-Abdominal Infections companies include MerLion Pharmaceuticals, AiCuris, Novartis, Allecra, AbbVie, AstraZeneca, Pfizer, Shionogi, Iterum Therapeutics, Nosopharm, and others are evaluating their lead assets to improve the Complicated Intra-Abdominal Infections treatment landscape.
• Key Complicated Intra-Abdominal Infections pipeline therapies in various stages of development include Sulopenem, Avibactam/aztreonam, and others.
• In February 2025, the FDA approved a fixed-dose intravenous combination of aztreonam and avibactam, along with metronidazole (Metrogel; Galderma Labs), for adults aged 18 and older with limited treatment options for complicated intra-abdominal infections (cIAI). This approval covers infections caused by Gram-negative bacteria such as Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae complex, Citrobacter freundii complex, and Serratia marcescens.
• In February 2025, AbbVie announced that the FDA had approved Emblaveo (aztreonam and avibactam) in combination with metronidazole for adults with complicated intra-abdominal infections (cIAI) and limited treatment options.

Request a sample and discover the recent breakthroughs happening in the Complicated Intra-Abdominal Infections pipeline landscape @ https://www.delveinsight.com/report-store/complicated-intra-abdominal-infections-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Complicated Intra-Abdominal Infections Overview
Complicated intra-abdominal infections (cIAI) are severe infections that extend beyond the hollow viscus of the abdomen, leading to peritonitis, abscess formation, or other serious complications. These infections often arise due to perforation, ischemia, trauma, or post-surgical complications, making them more challenging to treat than uncomplicated intra-abdominal infections. Complicated intra-abdominal infection symptoms may include severe abdominal pain, fever, nausea, vomiting, and signs of sepsis in more critical cases. If left untreated, complicated intra-abdominal infection complications can result in organ failure, septic shock, and even death.

Management of complicated intra-abdominal infections requires a combination of broad-spectrum antibiotics and surgical intervention, such as drainage or debridement, depending on the severity of the infection. Emerging therapies for complicated intra-abdominal infections focus on improving efficacy against multidrug-resistant pathogens and reducing hospitalization duration. Several clinical trials for complicated intra-abdominal infections are currently underway, evaluating novel antimicrobial agents and combination therapies to enhance patient outcomes. The complicated intra-abdominal infections clinical pipeline includes promising candidates from over 15 leading pharmaceutical companies, aiming to advance treatment options and combat resistance challenges.

Find out more about Complicated Intra-Abdominal Infections medication @ https://www.delveinsight.com/report-store/complicated-intra-abdominal-infections-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Complicated Intra-Abdominal Infections Treatment Analysis: Drug Profile
Sulopenem: Interim Therapeutics
Sulopenem is a novel agent that has demonstrated in vitro activity against gram-negative, gram-positive, and anaerobic bacteria resistant to other antibiotics. Sulopenem is being evaluated in phase 3 clinical trials for complicated intra-abdominal infections. The USFDA has granted Special Protocol Agreements and Qualified Infectious Disease Product Designations for Sulopenem.

Avibactam/aztreonam: AbbVie
Aztreonam / Avibactam is a combination being investigated for the treatment of complicated gram-negative bacterial infections. In combination, Avibactam inhibits the serine-β-lactamases and allows Aztreonam to work against MBL-producing pathogens. In November 2019, The Food and Drug Administration has granted Qualified Infectious Disease Product (QIDP) designation and Fast Track designation to Aztreonam/Avibactam for the treatment of complicated intra-abdominal infections.

Key Complicated Intra-Abdominal Infections Therapies and Companies
• Sulopenem: Interim Therapeutics
• Avibactam/aztreonam: AbbVie

Learn more about the novel and emerging Complicated Intra-Abdominal Infections pipeline therapies @ https://www.delveinsight.com/report-store/complicated-intra-abdominal-infections-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Complicated Intra-Abdominal Infections Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Oral
• Parenteral
• intravitreal
• Subretinal
• Topical.

By Molecule Type
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Scope of the Complicated Intra-Abdominal Infections Pipeline Report
• Coverage: Global
• Key Complicated Intra-Abdominal Infections Companies: MerLion Pharmaceuticals, AiCuris, Novartis, Allecra, AbbVie, AstraZeneca, Pfizer, Shionogi, Iterum Therapeutics, Nosopharm, and others.
• Key Complicated Intra-Abdominal Infections Pipeline Therapies: Sulopenem, Avibactam/aztreonam, and others.

Dive deep into rich insights for drugs used for Complicated Intra-Abdominal Infections treatment; visit @ https://www.delveinsight.com/report-store/complicated-intra-abdominal-infections-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Complicated Intra-Abdominal Infections Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Complicated Intra-Abdominal Infections Pipeline Therapeutics
6. Complicated Intra-Abdominal Infections Pipeline: Late-Stage Products (Phase III)
7. Complicated Intra-Abdominal Infections Pipeline: Late-Stage Products (Phase III)
8. Complicated Intra-Abdominal Infections Pipeline: Mid-Stage Products (Phase II)
9. Complicated Intra-Abdominal Infections Pipeline: Early Stage Products (Phase I)
10. Therapeutic Assessment
11. Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.